Currently out of the existing stock ratings of Etzer Darout, 64 are a BUY (71.11%), 26 are a HOLD (28.89%).

Etzer Darout

Work Performance Price Targets & Ratings Chart

Analyst Etzer Darout, currently employed at BMO, carries an average stock price target met ratio of 47.24% that have a potential upside of 46.17% achieved within 123 days.

Etzer Darout’s has documented 177 price targets and ratings displayed on 22 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on GMAB, Genmab AS at 08-Nov-2024.

Wall Street Analyst Etzer Darout

Analyst best performing recommendations are on FPRX (FIVE PRIME THERAPEUTICS).
The best stock recommendation documented was for MGNX (MACROGENICS) at 7/11/2022. The price target of $4 was fulfilled within 2 days with a profit of $0.45 (12.68%) receiving and performance score of 63.38.

Average potential price target upside

of $31.46 (22.45%) on SGEN (SEAGEN).
of $20.88 (90.59%) on MRUS (MERUS BV).
of $20.71 (14.35%) on ALNY (ALNYLAM PHARMACEUTICALS).

DMAC DiaMedica Therapeutics MGNX MacroGenics MIRM Mirum Pharmaceuticals VERV Verve Therapeutics CTMX CytomX Therapeutics EXEL Exelixis FATE Fate Therapeutics GMAB Genmab AS IMGN ImmunoGen MRUS Merus BV SGEN Seagen NUVL Nuvalent XNCR Xencor FPRX Five Prime Therapeutics ALNY Alnylam Pharmaceuticals YMAB Y mAbs Therapeutics ARVN Arvinas FTSV Forty Seven AZN AstraZeneca PLC ADR CCCC C4 Therapeutics IVA Inventiva Sa BNTX BioNTech SE

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Francois Brisebois (OPPENHEIMER)